Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Halozyme posts record revenue in 2022, eyes growth opportunities

Halozyme's strong financial performance in 2022 and positive revenue guidance for 2023 reflect a robust growth trajectory.
While facing integration challenges from acquisitions and potential competition, the company's strategic priorities and market engagement remain strong.
Exploring new collaborations, advancing product development, and maintaining a competitive edge present key opportunities for Halozyme.
Overall, Halozyme's proactive approach to growth and market dynamics positions it well for future success in the biopharmaceutical industry.

Halozyme reports robust Q1 earnings, poised for continued growth

Halozyme's strong Q1 performance and robust pipeline position them for continued revenue growth and leadership in subcutaneous drug delivery.
Challenges include regulatory impacts and legal uncertainties, but opportunities in new agreements, partnerships, and investments offer avenues for future growth.
Overall, Halozyme's strategic focus on innovation and revenue diversification bodes well for their long-term success and financial stability.

Halozyme reports robust Q2 growth, eyes new partnerships for revenue

Halozyme's Q2 2023 earnings call showcased strong financial performance, innovative product developments, and a positive outlook for revenue growth. The company's focus on expanding partnerships, maintaining revenue durability, and strategic capital allocation positions it well for future success in the biopharmaceutical market.

Halozyme excels in Q3, raises guidance, eyes market expansion

Halozyme's Q3 performance reflects financial strength and operational resilience, supported by strategic partnerships and revenue growth.
The company's focus on shareholder value through accelerated buybacks and commitment to innovation positions them for sustained success.
While challenges like market competition exist, Halozyme's opportunities in market expansion and revenue growth paint a positive outlook for the future.

Halozyme posts record earnings, eyes strategic growth opportunities ahead

Halozyme's strong financial results and positive outlook for 2024 position the company for continued growth and value creation.
Addressing challenges around market adoption and reimbursement processes will be key to unlocking the full potential of subcutaneous products.
Strategic partnerships, new product launches, and a focus on shareholder value enhancement underscore Halozyme's commitment to sustainable growth.

Halozyme reports robust Q1 growth, navigates biosimilar challenges

Halozyme's Q1 2024 performance demonstrated strong financial growth driven by royalties and milestone payments, supported by operational achievements and strategic capital allocation.
While facing challenges such as biosimilar competition and partnership complexities, the company remains well-positioned to capitalize on opportunities in subcutaneous delivery preferences and market expansion.
Overall, Halozyme's focus on revenue diversification, partnership expansion, and operational excellence sets a positive trajectory for sustained growth and resilience in the biopharmaceutical sector.

Halozyme posts strong Q3 results, raises guidance amid growth opportunities

Halozyme Therapeutics reported a stellar Q3 performance with significant revenue growth and raised guidance across key financial metrics. The company's partnerships, product portfolio, and strong financial position underscore its growth potential and market resilience. Halozyme is well-positioned to capitalize on opportunities for expansion and innovation in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Biogen

UnitedHealth Group

The healthcare sector will be one area of secular growth over the next decade. Several demand drivers will benefit the best healthcare stocks to buy across the entire value chain.

The 3 Best Healthcare Stocks to Buy in June 2024

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?

Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.

Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

Halozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of its ENHANZE rHuPH20 product in several EU countries until 2029.

Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU

Company Granted New European Patent for ENHANZE® Drug Delivery Platform SAN DIEGO , June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees.

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN DIEGO , June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees.

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

SAN DIEGO , June 4, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare conference. The presentation is scheduled for Tuesday, June 11 at 6:20 a.m.

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Updated Prescription Drug User Fee Act goal date of December 29, 2024 SAN DIEGO , May 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo ® (nivolumab) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. The updated goal date is December 29, 2024.

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Halozyme Therapeutics is among top biotech stocks to buy and watch, as the stock trades inside a buy zone following earnings.

Biotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout

BioMarin Pharmaceutical

Incyte

We live in the best of times where life is not capped at 45 or 50 years of age, all thanks to wonderful discoveries in the field of biotechnology. The resources being invested to produce new drugs and treatment methodologies are increasing day by day.

The 3 Best Biotech Stocks to Buy in May 2024

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: The Citizens JMP Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, May 14, 2024 Presentation Time: 7:00 a.m. PT / 10:00 a.m.

Halozyme to Participate in Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Jessica Fye - J.P. Morgan Michael DiFiore - Evercore ISI Mohit Bansal - Wells Fargo Corinne Johnson - Goldman Sachs Jason Butler - Citizens JMP Brendan Smith - TD Cowen Mitchell Kapoor - H.C.

Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.47 per share a year ago.

Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates

Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million, Representing YOY Growth of 10% - 19%, Adjusted EBITDA of $535 - $585 million, Representing YOY Growth of 26% - 37% and Non-GAAP Diluted EPS of $3.55 - $3.90, Representing YOY Growth of 28% - 41% Announced New $750 million Share Repurchase Program SAN DIEGO , May 7, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook. "We are pleased to report another quarter of double-digit revenue and earnings growth, which keeps us on track to meet our financial guidance for the full year.

HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

SAN DIEGO , April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors.

Mahesh Krishnan Elected to Halozyme's Board of Directors

Novavax

If you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks can range from pre-revenue startups to global pharmaceutical giants.

3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition

SAN DIEGO , April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, May 7, 2024 at 1:30 p.m.

Halozyme to Report First Quarter 2024 Financial and Operating Results

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Halozyme Therapeutics Stock (HALO)